Approximately 374 subjects with inadequately controlled T2DM on metformin will be recruited from North America and Europe. Subjects will be randomly assigned in a ratio of 1:1 to receive either bexagliflozin tablets, 20 mg, or sitagliptin tablets,100mg, once daily for 24 weeks. Subjects will continue to take metformin for the duration of the study.